• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

星形细胞瘤细胞系U 373 MG中人类NK1速激肽受体的特性研究

Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG.

作者信息

Heuillet E, Ménager J, Fardin V, Flamand O, Bock M, Garret C, Crespo A, Fallourd A M, Doble A

机构信息

Biology Department, Centre de Recherche de Vitry-Alfortville, Rhône-Poulenc Rorer, Vitry-sur-Seine, France.

出版信息

J Neurochem. 1993 Mar;60(3):868-76. doi: 10.1111/j.1471-4159.1993.tb03231.x.

DOI:10.1111/j.1471-4159.1993.tb03231.x
PMID:7679727
Abstract

The human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG was characterized using selective agonists and antagonists described for this receptor in the rat. Specific [3H]substance P binding sites were present on cell homogenates, whereas [3H]neurokinin A or [3H]-senktide binding sites were absent. The binding was saturable and reversible. The binding of [3H]substance P was inhibited by very low concentrations of [L-Pro9]substance P and [Sar9,Met(O2)11]substance P; septide was approximately 1,000-fold less potent. The most potent peptide antagonist was trans-4-hydroxy-1-(1H-indol-3-ylcarbonyl)-L-prolyl-N-methyl-N-(phe nylmethyl)-L- tyrosineamide. The rank order of potency for the nonpeptide antagonists was (S,S)-CP 96,345 > (+/-)-CP 96,345 > (+/-)-2-chlorobenzylquinuclidinone > (R,R)-CP 96,345 > RP 67580 > RP 68651. In [3H]-inositol-labeled cells, substance P stimulated phosphatidylinositol turnover. A good correlation was found when the abilities of NK1 receptor agonists for stimulating inositol phosphate production and for inhibiting [3H]substance P binding were compared. Similarly, the binding and functional assays were well correlated for the antagonists. As a result of its high sensitivity and selectivity, the U 373 MG cell line thus appears an excellent tool for investigating the pharmacology of the human NK1 receptor.

摘要

利用针对大鼠该受体描述的选择性激动剂和拮抗剂,对星形细胞瘤细胞系U 373 MG中的人NK1速激肽受体进行了表征。细胞匀浆中存在特异性的[3H]P物质结合位点,而不存在[3H]神经激肽A或[3H] - 速激肽结合位点。该结合是可饱和且可逆的。极低浓度的[L - Pro9]P物质和[Sar9,Met(O2)11]P物质可抑制[3H]P物质的结合;八肽的效力约低1000倍。最有效的肽拮抗剂是反式 - 4 - 羟基 - 1 - (1H - 吲哚 - 3 - 基羰基) - L - 脯氨酰 - N - 甲基 - N - (苯基甲基) - L - 酪氨酸酰胺。非肽拮抗剂的效力排序为(S,S) - CP 96,345 > (+/-) - CP 96,345 > (+/-) - 2 - 氯苄基奎宁环酮 > (R,R) - CP 96,345 > RP 67580 > RP 68651。在[3H] - 肌醇标记的细胞中,P物质刺激磷脂酰肌醇周转。比较NK1受体激动剂刺激肌醇磷酸生成和抑制[3H]P物质结合的能力时,发现两者具有良好的相关性。同样,拮抗剂的结合和功能测定也具有良好的相关性。由于其高灵敏度和选择性,U 373 MG细胞系因此似乎是研究人NK1受体药理学的极佳工具。

相似文献

1
Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG.星形细胞瘤细胞系U 373 MG中人类NK1速激肽受体的特性研究
J Neurochem. 1993 Mar;60(3):868-76. doi: 10.1111/j.1471-4159.1993.tb03231.x.
2
Characterization of NK1 and NK2 tachykinin receptors in guinea-pig and rat bronchopulmonary and vascular systems.豚鼠和大鼠支气管肺及血管系统中NK1和NK2速激肽受体的特性研究
Br J Pharmacol. 1994 Mar;111(3):759-68. doi: 10.1111/j.1476-5381.1994.tb14803.x.
3
SR 140333, a novel, selective, and potent nonpeptide antagonist of the NK1 tachykinin receptor: characterization on the U373MG cell line.
J Neurochem. 1994 Apr;62(4):1399-407. doi: 10.1046/j.1471-4159.1994.62041399.x.
4
Interaction of the substance P receptor antagonist RP 67580 with the rat brain NK1 receptor expressed in transfected CHO cells.P物质受体拮抗剂RP 67580与转染的CHO细胞中表达的大鼠脑NK1受体的相互作用。
Eur J Pharmacol. 1993 Mar 15;245(1):43-50. doi: 10.1016/0922-4106(93)90167-8.
5
Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists.与其他非肽类和肽类速激肽NK1拮抗剂相比,RP 67580在小鼠和大鼠中具有更高的效价。
Br J Pharmacol. 1993 Mar;108(3):793-800. doi: 10.1111/j.1476-5381.1993.tb12880.x.
6
Tachykinin NK1 receptor subtypes in the rat urinary bladder.大鼠膀胱中的速激肽NK1受体亚型
Br J Pharmacol. 1994 Mar;111(3):739-46. doi: 10.1111/j.1476-5381.1994.tb14800.x.
7
Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists.速激肽NK1受体拮抗剂对人胶质瘤细胞结合特性与功能拮抗作用之间的相关性
Eur J Pharmacol. 1999 Jun 25;374(3):435-43. doi: 10.1016/s0014-2999(99)00334-9.
8
Non-peptide antagonists, CP-96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors.非肽类拮抗剂CP-96,345和RP 67580可区分速激肽NK1受体中的物种变体。
Br J Pharmacol. 1993 Jan;108(1):223-7. doi: 10.1111/j.1476-5381.1993.tb13466.x.
9
Evidence that tachykinins relax the guinea-pig trachea via nitric oxide release and by stimulation of a septide-insensitive NK1 receptor.速激肽通过释放一氧化氮和刺激对七肽不敏感的NK1受体使豚鼠气管舒张的证据。
Br J Pharmacol. 1996 Mar;117(6):1270-6. doi: 10.1111/j.1476-5381.1996.tb16725.x.
10
Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist.肽模拟物MEN 11149的药理学,一种新型强效、选择性且口服有效的速激肽NK1受体拮抗剂。
Eur J Pharmacol. 1998 Jan 12;341(2-3):201-9. doi: 10.1016/s0014-2999(97)01453-2.

引用本文的文献

1
Peptidergic Systems and Cancer: Focus on Tachykinin and Calcitonin/Calcitonin Gene-Related Peptide Families.肽能系统与癌症:聚焦速激肽和降钙素/降钙素基因相关肽家族
Cancers (Basel). 2023 Mar 9;15(6):1694. doi: 10.3390/cancers15061694.
2
Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.基于碳水化合物的 NK1R 拮抗剂具有广谱抗癌活性。
J Med Chem. 2021 Jul 22;64(14):10350-10370. doi: 10.1021/acs.jmedchem.1c00793. Epub 2021 Jul 8.
3
Mitigation of Oxidation in Therapeutic Antibody Formulations: a Biochemical Efficacy and Safety Evaluation of N-Acetyl-Tryptophan and L-Methionine.
治疗性抗体制剂中氧化的缓解:N-乙酰色氨酸和 L-蛋氨酸的生化功效和安全性评估。
Pharm Res. 2018 Oct 2;35(11):222. doi: 10.1007/s11095-018-2467-5.
4
Substance P induces rapid and transient membrane blebbing in U373MG cells in a p21-activated kinase-dependent manner.P 物质通过依赖于 p21 激活激酶的方式诱导 U373MG 细胞发生快速和短暂的质膜泡状化。
PLoS One. 2011;6(9):e25332. doi: 10.1371/journal.pone.0025332. Epub 2011 Sep 23.
5
Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft.速激肽NK1受体拮抗剂对人胶质瘤U373 MG异种移植瘤的抗肿瘤活性
Br J Cancer. 2000 Jan;82(2):480-7. doi: 10.1054/bjoc.1999.0946.
6
Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors.P物质可激活携带速激肽NK1受体的人胶质瘤细胞系中与肿瘤生长相关的反应。
Br J Cancer. 1999 Jan;79(2):236-43. doi: 10.1038/sj.bjc.6690039.
7
Interactions between tachykinins and diverse, human nicotinic acetylcholine receptor subtypes.速激肽与多种人类烟碱型乙酰胆碱受体亚型之间的相互作用。
Neurochem Res. 1996 Oct;21(10):1245-57. doi: 10.1007/BF02532402.
8
The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.新型强效选择性非肽类速激肽NK1受体拮抗剂GR203040的药理学
Br J Pharmacol. 1995 Dec;116(8):3149-57. doi: 10.1111/j.1476-5381.1995.tb15117.x.